Emerging epilepsy models: Insights from mice, flies, worms and fish

Current Opinion in Neurology

Volumn 20, Issue 2, 2007, Pages 164-168

  Baraban, Scott C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epilepsy; Invertebrate; Model; Organism; Seizure

Indexed keywords

CARBAMAZEPINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ETIRACETAM; LAMOTRIGINE; LORAZEPAM; MULTIDRUG RESISTANCE PROTEIN; OXCARBAZEPINE; PARALDEHYDE; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID;

AGITATION; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONVULSION; DIZZINESS; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TOLERANCE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; EPILEPTOGENESIS; FOCAL EPILEPSY; FRONTAL LOBE EPILEPSY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEART ARRHYTHMIA; HORMONE SUBSTITUTION; HOSTILITY; HUMAN; HYPOTENSION; INFLAMMATION; INTRACTABLE EPILEPSY; LIVER DYSFUNCTION; MENTAL INSTABILITY; MONOTHERAPY; MULTIDRUG RESISTANCE; MYOCLONUS EPILEPSY; NAUSEA; NERVOUSNESS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; PERSONALITY DISORDER; PREGNANCY; PREVALENCE; PROGNOSIS; PROMOTER REGION; REMISSION; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; SOMNOLENCE; TONIC CLONIC SEIZURE; TREATMENT FAILURE;

ANIMALS; DIPTERA; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPILEPSY; FISHES; HUMANS; MICE; NEMATODA;

EID: 33947148529     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328042bae0     Document Type: Review

References (50)

1. Purpura DP, Penry JK, Tower DB, et al. Experimental models of epilepsy: A manual for the laboratory worker. New York: Raven Press; 1972.
2. Pitkänen A, Schwartzkroin PA, Moshé SL. Models of seizures and epilepsy. Boston: Elsevier Academic Press; 2006. • This thoughtful and well organized textbook features updates on widely used rat kindling models, in-vitro seizure preparations, and newer genetic models.
3. Cortez MA, Perez Velazquez JL, Snead OC 3rd. Animal models of epilepsy and progressive effects of seizures. Adv Neurol 2006; 97:293-304.
4. Seyfried TN, Glaser GH. A review of mouse mutants as genetic models of epilepsy. Epilepsia 1985; 26:143-150.
5. Loscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and poststatus epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002; 50:105-123.
6. Brenner R, Chen QH, Vilaythong A, et al. BK channel b4 subunit reduces dentate gyrus excitability and protects against temporal lobe seizures. Nat Neurosci 2005; 8:1752-1759. •• The authors showed that a β4 subunit represses the role played by BK channel activation in action potential repolarization. Surprisingly, conversion to a fast-gated BK channel in β4 null neurons reduced spike frequency adaptation, increasing firing rate and seizures.
7. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9:1142-1149.
8. Wang D, Pascual JM, Yang H, et al. A mouse model for Glut-1 haploinsufficiency. Hum Mol Genet 2006; 15:1169-1179.
9. Fonck C, Cohen BN, Nashmi R, et al. Novel seizure phenotype and sleep disruptions in knock-in mice with hypersensitive α4* nicotinic receptors. J Neurosci 2005; 25:11396-11411.
10. Schauwecker PE, Steward O. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci U S A 1997; 94:4103-4108.
11. Kearney JA, Yang Y, Beyer B, et al. Severe epilepsy resulting from genetic interaction between Scn2a and Kcnq2. Hum Mol Genet 2006; 15:1043-1048.
12. Frankel WN, Beyer B, Maxwell CR, et al. Development of a new genetic model for absence epilepsy: spike-wave seizures in C3H/He and backcross mice. J Neurosci 2005; 25:3452-3458. • This paper demonstrates that mouse substrains and crosses involving C3H/He have a high incidence of spike-wave discharges, thus suggesting new models for absence epilepsy.
13. Cobos I, Calcagnotto ME, Vilaythong AJ, et al. Mice lacking Dlx1 show subtype-specific loss of interneurons, reduced inhibition and epilepsy. Nat Neurosci 2005; 8:1059-1068.
14. Binder DK, Yao X, Zador Z, et al. Increased seizure duration and slowed potassium kinetics in mice lacking aquaporin-4 water channels. Glia 2006; 53:631-636.
15. Ganetzky B. Genetic analysis of ion channel dysfunction in Drosophila. Kidney Int 2000; 57:766-771.
16. Titus SA, Warmke JW, Ganetzky B. The Drosophila erg K+ channel polypeptide is encoded by the seizure locus. J Neurosci 1997; 17:875-881.
17. Ganetzky B, Wu CF. Neurogenetics of membrane excitability in Drosophila. Annu Rev Genet 1986; 20:13-44.
18. Lee J, Wu CF. Electroconvulsive seizure behavior in Drosophila: analysis of the physiological repertoire underlying a stereotyped action pattern in bang-sensitive mutants. J Neurosci 2002; 22:11065-11079.
19. Lee J, Wu CF. Genetic modifications of seizure susceptibility and expression by altered excitability in Drosophila Na+ and K+ channel mutants. J Neurophysiol 2006; 96:2465-2478.
20. Pinel JPJ, Rovner LI. Experimental epileptogenesis: kindling-induced epilepsy in rats. Exp Neurol 1978; 58:190-202.
21. Racine RJ. Modification of seizure activity by electrical brain stimulation. I. Afterdischarge threshold. Electroencephalogr Clin Neurophysiol 1972; 32:269-280.
22. Reynolds ER, Stauffer EA, Feeney L, et al. Treatment with the antiepileptic drugs phenytoin and gabapentin ameliorates seizure and paralysis of Drosophila bang-sensitive mutants. J Neurobiol 2004; 58:503-513.
23. Stilwell GE, Saraswati S, Littleton JT, et al. Development of a Drosophila seizure model for in vivo high-throughput drug screening. Eur J Neurosci 2006; 24:2211-2222. • An important manuscript detailing simple methodologies to screen compounds for anticonvulsive potential in flies. Twenty-two compounds were screened in a picrotoxin protection assay.
24. Krall RL, Penry JK, White BG, et al. Antiepileptic drug development. II: Anticonvulsant drug screening. Epilepsia 1978; 19:393-408.
25. Shandra AA, Mazarati AM, Godlevsky LS, et al. Chemical kindling: implications for antiepileptic drugs - sensitive and resistant epilepsy models. Epilepsia 1996; 37:269-274.
26. Spradling AC, Stern DM, Kiss I, et al. Gene disruptions using P transposable elements: an integral component of the Drosophila genome project. Proc Natl Acad Sci U S A 1995; 92:10824-10830.
27. Noebels JL. The biology of epilepsy genes. Annu Rev Neurosci 2003; 26:599-625.
28. Kuebler D, Tanouye MA. Modifications of seizure susceptibility in Drosophila. J Neurophysiol 2000; 83:998-1009.
29. Kuebler D, Zhang H, Ren X, et al. Genetic suppression of seizure susceptibility in Drosophila. J Neurophysiol 2001; 86:1211-1225.
30. Pavlidis P, Tanouye MA. Seizures and failures in the giant fiber pathway of Drosophila bang-sensitive paralytic mutants. J Neurosci 1995; 15:5810-5819.
31. - cotransporter gene kazachoc (kcc) increases seizure susceptibility in Drosophila. J Neurosci 2006; 26:8943-8954. • This presents an interesting observation that links observations made in flies with reported roles for these co-transporters in rodents.
32. Rivera C, Voipio J, Kaila K. Two developmental switches in GABAergic signalling: the K+-Cl- cotransporter KCC2 and carbonic anhydrase CAVII. J Physiol 2005; 562:27-36.
33. Haglund MM, Hochman DW. Furosemide and mannitol suppression of epileptic activity in the human brain. J Neurophysiol 2005; 54:907-918.
34. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005; 11:1205-1213.
35. Ross BM, Eder K, Moszczynska A, et al. Abnormal activity of membrane phospholipid synthetic enzymes in the brain of patients with Friedreich's ataxia and spinocerebellar atrophy type-1. Mov Disord 2000; 15:294-300.
36. Kato M, Dobyns WB. Lissencephaly and the molecular basis of neuronal migration. Hum Mol Genet 2003; 12 (Spec No 1):R89-R96.
37. Sengupta P, Colbert HA, Kimmel BE, et al. The cellular and genetic basis of olfactory responses in Caenorhabditis elegans. Ciba Found Symp 1993; 179:235-244.
38. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science 1998; 282:2028-2033.
39. Weimer RM, Richmond JE, Davis WS, et al. Defects in synaptic vesicle docking in unc-18 mutants. Nat Neurosci 2003; 6:1023-1030.
40. Cronin CJ, Feng Z, Schafer WR. Automated imaging of C. elegans behavior. Methods Mol Biol 2006; 351:241-251.
41. Dawe AL, Caldwell KA, Harris PM, et al. Evolutionarily conserved nuclear migration genes required for early embryonic development in Caenorhabditis elegans. Dev Genes Evol 2001; 211:434-441.
42. Cockell MM, Baumer K, Gonczy P. lis-1 is required for dynein-dependent cell division processes in C. elegans embryos. J Cell Sci 2004; 117:4571-4582.
43. Williams SN, Locke CJ, Braden AL, et al. Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in Caenorhabditis elegans. Hum Mol Genet 2004; 13:2043-2059.
44. Locke CJ, Williams SN, Schwarz EM, et al. Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in C. elegans. Brain Res 2006; 1120:23-34.
45. Grabher C, Look AT. Fishing for cancer models. Nat Biotechnol 2006; 24:45-46.
46. Sadler KC, Amsterdam A, Soroka C, et al. A genetic screen in zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease. Development 2005; 132:3561-3572.
47. Baraban SC, Taylor MR, Castro PA, et al. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-Fos expression. Neuroscience 2005; 131:759-768.
48. Keogh BP, Cordes D, Stanberry L, et al. BOLD-fMRI of PTZ-induced seizures in rats. Epilepsy Res 2005; 66:75-90.
49. Corey DR, Abrams JM. Morpholino antisense oligonucleotides: tools for investigating vertebrate development. Genome Biol 2001; 2:REVIEWS1015.
50. Kawakami K. Transposon tools and methods in zebrafish. Dev Dyn 2005; 234:244-254.